Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enzalutamide - Astellas Pharma/Medivation

Drug Profile

Enzalutamide - Astellas Pharma/Medivation

Alternative Names: ASP-9785; MDV-3100; Xtandi

Latest Information Update: 02 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California at Los Angeles; University of Texas M. D. Anderson Cancer Center
  • Developer Astellas Pharma; Bristol-Myers Squibb; Clovis Oncology; H. Lee Moffitt Cancer Center and Research Institute; M. D. Anderson Cancer Center; Medivation; National Cancer Institute (USA); Queen Mary University of London; The Prostate Cancer Clinical Trials Consortium; University of California, Davis; University of Chicago; University of Rochester
  • Class Antineoplastics; Benzamides; Fluorobenzenes; Imidazolidines; Nitriles; Small molecules; Thiones
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase II Bladder cancer; Breast cancer; Endometrial cancer; Ovarian cancer; Salivary gland cancer
  • No development reported Pancreatic cancer
  • Discontinued Liver cancer

Most Recent Events

  • 28 Nov 2019 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO, Capsule)
  • 28 Nov 2019 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Hormone refractory) in USA (PO)
  • 27 Nov 2019 Clovis Oncology plans the phase I RAMP trial for Prostate Cancer (Metastatic disease, Combination therapy, Hormone refractory) (NCT04179396)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top